Phytolderived novel isoprenoid immunostimulants

Frontiers in Immunology

Volumn 3, Issue MAR, 2012, Pages

  Chowdhury, Roshni Roy ^a   Ghosh, Swapan K ^a  

^a INDIANA STATE UNIVERSITY   (United States)

Author keywords

Activation of innate immunity; AntibodyandCTLresponse; Cytokinemicroenvironment; Immunostimulants; Inflammasome; Isoprenoid adjuvants; Phytol derivatives; Vaccine fficacy

Indexed keywords

EID: 84873076814     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00049     Document Type: Review

References (107)

1. Aachoui, Y. (2011). Novel Phytol-Derived Immunostimulants (PHIS-01) for Enhancement of Vaccine Efficacy: A Comparative Study. Dissertation, Indiana State University, Terre Haute.
2. Aachoui, Y., Schulte, M. L., Fitch, R. W., and Ghosh, S. K. (2011a). Synthetic adjuvants for vaccine formulations: evaluation of new phytol derivatives in induction and persistence of specific immune response. Cell. Immunol. 271, 308-318.
3. Aachoui, Y., Chowdhury, R. R., Fitch, R. W., and Ghosh, S. K. (2011b). Ghosh molecular signatures of phytolderived immunostimulants in the context of chemokinecytokine microenvironment and enhanced immune response. Cell. Immunol. 271, 227-238.
4. Allan, S. (2008). Vaccines: explaining alum: immunologists' dirty little secret. Nat. Rev. Immunol. 8, 320.
5. Asa,P. B.,Cao,Y.,and Garry,R. F. (2000). Antibodies to squalene in Gulf War syndrome. Exp. Mol. Pathol. 68, 55-64.
6. Azuma, I. (1992). Synthetic immunoadjuvants: application to nonspecific host stimulation and potentiation of vaccine immunogenicity.Vaccine 10, 1000-1006.
7. Bakkali, F., Averbeck, S., Averbeck, D., and Idaomar, M. (2008). Idaomar biological effects of essential oils -areview.Food Chem. Toxicol. 46, 446-475.
8. Banzhoff, A., Gasparini, R., Laghi-Pasini, F., Staniscia, T., Durando, P., Montomoli, E., Capecchi, P. L., di Giovanni, P., Sticchi, L., Gentile, C., Hilbert, A., Brauer, V., Tilman, S., and Podda, A. (2009). MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in nonelderly and elderly adults. PLoS ONE 4, e4384. doi:10.1371/journal.pone.0004384
9. Banzhoff, A., Pellegrini, M., Del Giu-Dice, G., Fragapane, E., Groth, N., and Podda, A. (2008). MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respi. Viruses 2, 243-249.
10. Baudner, B. C., Ronconi, V., Casini, D., Tortoli, M., Kazzaz, J., Singh, M., Hawkins, L. D., Wack, A., and O'Hagan, D. T. (2009). MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm. Res. 26, 1477-1485.
11. Baxter, J. H. (1968). Absorption of chlorophyll phytol in normal man and in patients with Refsum's disease. J. Lipid Res. 9, 636-641.
12. Benísek, Z., Süli, J., Eliás, D., Lenhardt, L., Ondrejková, A., Ondrejka, R., Svrcek, S., and Bajová, V. (2004). Experimental squalene adjuvant II. Harmlessness and local reactogenicity. Vaccine 22, 3470-3474.
13. Bifulco, M. (2005). Role of the isoprenoid pathway in ras transforming activity, cytoskeleton organization, cell proliferation and apoptosis. Life Sci. 77, 1740-1749.
14. Billiau, A., and Matthys, P. (2001). Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J. Leukoc. Biol. 70, 849-860.
15. Blagowechensky, N. (1938). Durée du séjour de l'antigène dans l'organisme et immunité. Rev. Immunol. 4, 161.
16. Brewer, J. M., Conacher, M., Hunter, C. A., Mohrs, M., Brombacher, F., andAlexander,J. (1999).Aluminium hydroxide adjuvant initiates strong antigenspecific Th2 responses in the absence of IL-4-or IL-13-mediated signaling. J. Immunol. 163, 6448-6454.
17. Butler, N. R., Voyce, M. A., Burland, W. L., and Hilton, M. L. (1969). Advantages of aluminium hydroxide adsorbed combined diphtheria, tetanus, and pertussis vaccines for the immunization of infants. Br. Med. J. 1, 663-666.
18. Casadevall,A.,and Pirofski,L.A. (1998). Use of licensed vaccines for active immunization of the immunocompromised host. Clin. Microbiol. Rev. 11, 1-26.
19. Cox, J. C., Sjölander, A., and Barr, I. G. (1998). ISCOMs and other saponin based adjuvants. Adv. Drug Deliv. Rev. 32, 247-271.
20. Cribbs, D. H., Ghochikyan, A., Vasilevko, V., Tran, M., Petrushina, I., Sadzikava, N., Babikyan, D., Kesslak, P., Kieber-Emmons, T., Cotman, C. W., and Agadjanyan, M. G. (2003). Adjuvant dependent modulation of Th1 and Th2 responses to immunization with β amyloid. Int. Immunol. 15, 505-514.
21. Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A.,Vosters, O., Vanderheyde, N., Schiavetti, F., Larocque, D., Van Mechelen, M., and Garçon, N. (2009). AS04, an aluminum saltand TLR4 agonistbased adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183, 6186-6197.
22. Dvorak,A. M.,and Dvorak,H. F. (1974). Structure of Freund's complete and incomplete adjuvants. Relation of adjuvanticity to structure. Immunology 27, 99-114.
23. Elson, C. E., and Yu, S. G. (1994). The chemoprevention of cancer by mevalonatederived constituents of fruits and vegetables. J. Nutr. 124, 607-614.
24. Estrada, A., Li, B., and Laarveld, B. (1998). Adjuvant action of Chenopodium quinoa saponins on the induction of antibody responses to intragastric and intranasal administered antigens in mice. Comp. Immunol. Microbiol. Infect. Dis. 21, 225-236.
25. Geiera, D. A., King, P. G., and Geierc, M. R. (2009). Mitochondrial dysfunction, impaired oxidativereduction activity, degeneration, and death in human neuronal and fetal cells induced by lowlevel exposure to thimerosal and other metal compounds. Toxicol. Environ. Chem. 91, 735-749.
26. Ghosh, S. K. (2012). Phytol derived immunoadjuvants and their use in vaccine formulations. United States Patent 8088395.
27. Ghosh, S. K., and Aachoui, Y. (2011). Immune enhancement by novel vaccine adjuvants in autoimmuneprone NZB/W F1 mice: relative efficacy and safety. BMC Immunol. 12, 61. doi:10.1186/1471-2172-12-61
28. Glomset, J. A., Gelb, M. H., and Farnsworth, C. C. (1990). Prenyl proteins in eukaryotic cells: a new type of membrane anchor. Trends Biochem. Sci. 15, 139-142.
29. Granoff, D. M., McHugh, Y. E., Raff, H. V., Mokatrin, A. S., and Van Nest, G. A. (1997). MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine. Infect. Immun. 65, 1710-1715.
30. Gupta, R. K., Relyveld, E. H., Lindblad, E. B., Bizzini, B., Ben-Efraim, S., and Gupta, C. K. (1993). Adjuvants -a balance between toxicity and adjuvanticity. Vaccine 11, 293-306.
31. Harrewijn, P., van Oosten, A. M., and Piron, P. G. M. (2001). Natural terpenoids as messengers. A multidisciplinary study of their production, biological functions and practical applications. Ann. Bot. 90, 299-300
32. Heinemann, L., Woodfield, L., Amer, M., and Hibma, M. (2008). Effective induction of type 1 helper IgG2a and cytotoxic T-cell responses in mice following immunization with human papillomavirus type 16 E2 in MF59. Viral Immunol. 21, 225-233.
33. Holm, B. C., Lorentzen, J. C., and Bucht, A. (2004). Adjuvant oil induces waves of arthritogenic lymph node cells prior to arthritis onset. Clin. Exp. Immunol. 137, 59-64.
34. Holmdahl, R., Lorentzen, J. C., Lu, S., Olofsson, P., Wester, L., Holmberg, J., and Pettersson, U. (2001). Arthritis induced in rats with nonimmunogenic adjuvants as models for rheumatoid arthritis. Immunol. Rev. 184, 184-202.
35. Isman, M. B. (2006). Botanical insecticides, deterrents, and repellents in modern agriculture and an increasingly regulated world. Annu. Rev. Entomol. 51, 45-66.
36. Janeway, C. (1989). Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54, 1-13.
37. Kagoura, M., Matsui, C., and Moro-Hashi, M. (1999). Phytol is a novel tumor promoter on ICR mouse skin. Jpn. J. Cancer Res. 4, 377-384.
38. Kalvodova, L. (2010). Squalenebased oilinwater emulsion adjuvants perturb metabolism of neutral lipids and enhance lipid droplet formation. Biochem. Biophys. Res. Commun. 393, 350-355.
39. Kazanietz, M. (2005). Targeting protein kinase C and "nonkinase" phorbol ester receptors: emerging concepts and therapeutic implications. Biochim. Biophys. Acta 1754, 296-304.
40. Kensil, C. R., and Kammer, R. (1998). QS-21: a watersoluble triterpene glycoside adjuvant. Expert Opin. Investig. Drugs 7, 1475-1482.
41. Kensil, C. R., Liu, G., Anderson, C., and Storey, J. (2006). Effects of QS21 on innate and adaptive immune responses. Vaccin. Adjuvants 221-234.
42. Kono, H., and Rock, K. L. (2008). How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8, 279-289.
43. Krishnan, L., Dicaire, C. J., Patel, G. B., and Sprott, G. D. (2000). Archaeosome vaccine adjuvants induce strong humoral, cellmediated, and memory responses: comparison to conventional liposomes and alum. Infect. Immun. 68, 54-63.
44. Kuroda, Y., Nacionales, D. C., Akaogi, J., Reeves, W. H., and Satoh, M. (2004). Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed. Pharmacother. 58, 325-337.
45. Lederer, E. (1980). Synthetic immunostimulants derived from the bacterial cell wall. J. Med. Chem. 8, 819-825.
46. Lee, I. F., van den Elzen, P., Tan, R., and Priatel, J. J. (2011). NKT cells are required for complete Freund's adjuvantmediated protection from autoimmune diabetes. J. Immunol. 187, 2898-2904.
47. Lévesque, S., Martinez, G., and Fair-Brother, J. M. (2007). Improvement of adjuvant systems to obtain a costeffectiveproductionofhighlevelsof specific IgY. Poult. Sci. 86, 630-635.
48. Li, H. (2009). Impact of Immuno-Adjuvants on Anti-Lymphoma Vaccine Efficacy. Ph.D. thesis, Indiana State University, Terre Haute.
49. Li, H., Willingham, S. B., Ting, J. P., and Re, F. (2008). Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J. Immunol. 181, 17-21.
50. Lim, S.-K. (2003). Freund adjuvant induces TLR2 but not TLR4 expression in the liver of mice. Int. Immunopharmacol. 3, 115-118.
51. Lim, S. Y., and Ghosh, S. K. (2003). Autoreactive responses to an environmental factor: 1 phthalate induces antibodies exhibiting anti-DNA specificity. Immunology 110, 482-492.
52. Lim, S. Y., and Ghosh, S. K. (2004). Autoreactive responses to environmental factors: 3. Mouse strainspecific differences in induction and regulation of anti-DNA antibody responses due to phthalateisomers. J. Autoimmun. 25, 33-45.
53. Lim, S. Y., Meyer, M., Kjonaas, R. A., and Ghosh, S. K. (2006a). Phytolbased novel adjuvants in vaccine formulation 1 assessment of safety and efficacy during stimulation of humoral and cellmediated immune responses. J. Immune Based Ther. Vaccines 4, 5.
54. Lim, S. Y., Bauermeister, A., Kjonaas, R. A.,and Ghosh,S. K. (2006b). Phytolbased novel adjuvants in vaccine formulation: 2 assessment of efficacy in the induction of protective immune responses to lethal bacterial infections in mice. J. Immune Based Ther. Vaccines 4, 5.
55. Lindblad, E. (1995). Aluminium adjuvants. The Theory and Practical Application of Adjuvants. Chichester: John Wiley & Sons Ltd., 21-35.
56. Maa, Y. F., Zhao, L., Payne, L. G., and Chen, D. (2002). Stabilization of alumadjuvanted vaccine dry powder formulations: mechanism and application. J. Pharm. Sci. 92, 319-332.
57. Maimone, T. J., and Baran, P. S. (2007). Modern synthetic efforts toward biologically active terpenes. Nat. Chem. Biol. 3, 396-407.
58. Marchkesbery, W. R., Ehmann, W. D., Hossain, T. I., Alauddin, M., and Goodin, D. T. (1981). Instrumental neutron activation analysis of brain aluminum in Alzheimer disease and aging. Ann. Neurol. 10, 511-516.
59. Marciani, D. J., Pathak, A. K., Reynolds, R. C., Seitz, L., and May, R. D. (2001). Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins. Int. Immunopharmacol. 1, 813-818.
60. Marciani, D. J., Press, J. B., Reynolds, R. C., Pathak, A. K., Pathak, V., Gundy, L. E., Farmer, J. T., Koratich, M. S., and May, R. D. (2000). Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine 18, 3141-3151.
61. Marrack, P., McKee, A. S., and Munks, M. W. (2009). Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9, 287-293.
62. Mastelic, B., Ahmed, S., Egan, W. M., Del Giudice, G., Golding, H., Gust, I., Neels, P., Reed, S. G., Sheets, R. L., Siegrist, C. A., and Lam-Bert, P. H. (2010). Mode of action of adjuvants: implications for vaccine safety and design. Biologicals 38, 594-601.
63. Matthys, P., Vermeire, K., Mitera, T., Heremans, H., Huang, S., Schols, D., De Wolf-Peeters, C., and Billiau, A. (1999). Enhanced autoimmune arthritis in IFN-gamma receptordeficient mice is conditioned by mycobacteria in Freund's adjuvant and by increased expansion of Mac-1+ myeloid cells. J. Immunol. 163, 3503-3510.
64. Mbow, M. L., De Gregorio, E., and Ulmer, J. B. (2011). Alum's adjuvant action: grease is the word. Nat. Med. 17, 415-416.
65. McInerney, M. F., Pek, S. B., and Thomas, D. W. (1991). Prevention of insulitis and diabetes onset by treatment with complete Freund's adjuvant in NOD mice. Diabetes 40, 715-725.
66. McKee, A. S., MacLeod, M. K., Kappler, J. W., and Marrack, P. (2010). Immune mechanisms of protection: can adjuvants rise to the challenge? BMC Biol. 8, 37. doi:10.1186/1741-7007-8-37
67. Medzhitov, R., and Pasare, C. (2003). Toll pathwaydependent blockade of CD4+CD25+ T cellmediated suppression by dendritic cells. Science 299, 1033-1036.
68. Mo, H., and Elson, C. E. (2004). Studies of the isoprenoidmediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp. Biol. Med. (Maywood) 229, 567-585.
69. Montagnani, S., Tuccori, M., Lombardo, G., Testi, A., Mantarro, S., Rug-Giero, E., and Blandizzi, C. (2011). Autoimmune hemolytic anemia following MF59-adjuvanted influenza vaccine administration: a report of two cases. Ann. Pharmacother. 45,e8.
70. Mosca, F., Tritto, E., Muzzi, A., Monaci, E., Bagnoli, F., Iavarone, C., O'Hagan, D., Rappuoli, R., and De Gregorio, E. (2008). Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl. Acad. Sci. U.S.A. 105, 10501-10506.
71. Norton, E. B., Clements, J. D., Voss, T. G., and Cárdenas-Freytag, L. (2010). Prophylactic Administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. J. Virol. 84, 2983-2995.
72. Oda, K., Matsuda, H., Murakami, T., Katayama, S., Ohgitani, T., and Yoshikawa, M. (2000). Adjuvant and haemolytic activities of 47 saponins derived from medicinal and food plants. Biol. Chem. 381, 67-74.
73. Oscherwitz, J., Hankenson, F. C., Yu, F., and Cease, K. B. (2006). Lowdose intraperitoneal Freund's adjuvant: toxicity and immunogenicity in mice using an immunogen targeting amyloid-β peptide. Vaccine 24, 3018-3025.
74. Ott, G., Singh, M., Kazzaz, J., Briones, M., Soenawan, E., Ugozzoli, M., and O'Hagan, D. T. (2002). A cationic submicron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines. J. Control. Release 79, 1-5.
75. Pasare, C., and Medzhitov, R. (2004). Tolldependent control mechanisms of CD4 T cell activation. Immunity 21, 733-741.
76. Peng, S. L., Moslehi, J., and Craft, J. (1997). Roles of interferongamma and interleukin-4 in murine lupus. J. Clin. Invest. 99, 1936-1946.
77. Petrovsky, N., and Aguilar, J. C. (2004). Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 82, 488-496.
78. Pickett, J. A., and Gibson, R. W. (1983). Wild potato repels aphids by release of aphid alarm pheromone. Nature 302, 608-609.
79. Raghavendra, V., Tanga, F. Y., and DeLeo, J. A. (2004). Complete Freunds adjuvantinduced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur. J. Neurosci. 20, 467-473.
80. Rajput, Z. I., Hu, S. H., Xiao, C. W., and Arijo, A. G. (2007). Adjuvant effects of saponins on animal immune responses. J. Zhejiang Univ. Sci. B 8, 153-161.
81. Reddy, L. H., and Couvreur, P. (2009). Squalene: a natural triterpene for use in disease management and therapy. Adv. Drug Deliv. Rev. 61, 1412-1426.
82. Reeves, W. H., Lee, P. Y., Weinstein, J. S., Satoh, M., and Lu, L. (2009). Induction of autoimmunity by pristane and other naturallyoccurring hydrocarbons. Trends Immunol. 30, 455-464.
83. Rhodes, J., Chen, H., Hall, S. R., Beesley, J. E., Jenkins, D. C., Collins, P., and Zheng, B. (1995). Therapeutic potentiation of the immune system by costimulatory Schiffbaseforming drugs. Nature 377, 71-75.
84. Rilling, H. C., Breunger, E., Epstein, W. W., and Crain, P. F. (1990). Prenylated proteins: the structure of the isoprenoid group. Science 247, 318-320.
85. Salkowski, C. A., Detore, G. R., and Vogel, S. N. (1997). Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect. Immun. 65, 3239.
86. Satoh, M., Kuroda, Y., Yoshida, H., Behney, K. M., Mizutani, A., Akaogi, J., Nacionales, D. C., Lorenson, T. D., Rosenbauer, R. J., and Reeves, W. H. (2003). Induction of lupus autoantibodies by adjuvants. J. Autoimmun. 21, 1-9.
87. Seubert, A., Calabro, S., Santini, L., Galli, B., Genovese, A., Valentini, S., Aprea, S., Colaprico, A., D'Oro, U., Giuliani, M. M., Pallaoro, M., Pizza, M., O'Hagan, D. T., Wack, A., Rappuoli, R., and De Gregorio, E. (2011). Adjuvanticity of the oilinwater emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc. Natl. Acad. Sci. U.S.A.108, 11169-11174.
88. Seubert, A., Monaci, E., Pizza, M., O'Hagan, D. T., and Wack,A. (2008). The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol. 180, 5402-5412.
89. Shieh, H. L., Hansen, H., Zhu, J., and Riedel, H. (1995). Differential protein kinase C ligand regulation detected in vivo by a phenotypic Chowdhury and Ghosh Phytolderived novel isoprenoid immunostimulants yeast assay. Mol. Carcinog. 12, 166-176.
90. Skene, C. D., and Sutton, P. (2006). Saponinadjuvanted particulate vaccines for clinical use. Methods 40, 53-59.
91. Smith, K. M., Brewer, J. M., Rush, C. M., Riley, J., and Garside, P. (2004). In vivo generated Th1 cells can migrate to B cell follicles to support B cell responses. J. Immunol. 173, 1640-1646.
92. Soltysik, S., Wu, J. Y., Recchia, J., Wheeler, D. A., Newman, M. J., Coughlin, R. T., and Kensil, C. R. (1995). Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine 13, 1403-1410.
93. Song, X., and Hu, S. (2009). Adjuvant activities of saponins from traditional Chinese medicinal herbs. Vaccine 27, 4883-4890.
94. Spanedda, M.V., Heurtault, B.,Weidner, S., Baehr, C., Boeglin, E., Beyrath, J., Milosevic, S., Bourel-Bonnet, L., Fournel, S., and Frisch, B. (2010). Novel powerful watersoluble lipid immunoadjuvants inducing mouse dendritic cell maturation and B cell proliferation using TLR2 pathway. Bioorg. Med. Chem. Lett. 20, 1869-1872.
95. Sparg, S. G., Light, M. E., and van Staden, J. (2004). Biological activities and distribution of plant saponins. J. Ethnopharmacol. 94, 219-243.
96. Staats, H. F., and Ennis, F. A. Jr. (1999). IL-1 Is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. J. Immunol. 162, 6141-6147.
97. Stills, H. F. Jr. (2005). Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR J. 46, 280-293.
98. Straw, B. E., MacLachlan, N. J., Cor-Bett, W. T., Carter, P. B., and Schey, H. M. (1985). Comparison of tissue reactions produced by Haemophilus pleuropneumoniae vaccines made with six different adjuvants in swine. Can. J. Comp. Med. 49, 149-151.
99. Strominger, J. L. (2007). Bacterial cell walls, innate immunity and immunoadjuvants. Nat. Immunol. 8, 1269-1271.
100. Sun, H. X., Xie, Y., and Ye, Y. P. (2009). Advances in saponinbased adjuvants. Vaccine 27, 1787-1796.
101. The lowtoxicity versions of. L.P.S., MPL., adjuvant and RC529, are efficient adjuvants for CD4, T., cells
102. Thoppil, R. J., and Bishayee, A. (2011). Terpenoids as potential chemopreventive and therapeutic agents in liver cancer. WorldJ.Hepatol.3, 228-249.
103. Traquina, P., Morandi, M., Contorni, M., and Van Nest, G. (1996). MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J. Infect. Dis. 174, 1168-1175.
104. Wilner, B. I., Evers, M. A., Troutman, H. D., Trader, F. W., and Mclean, I. W. (1963). Vaccine potentiation by emulsification with pure hydrocarbon compounds. J. Immunol. 91, 210-229.
105. Yip, H. C., Karulin, A. Y., Tary-Lehmann, M., Hesse, M. D., Radeke, H., Heeger, P. S., Trezza, R. P., Heinzel, F. P., Forsthuber, T., and Lehmann, P. V. (1999). Adjuvantguided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J. Immunol. 62, 3942-3949.
106. Yoshino, S., Sasatomi, E., and Ohsawa, M. (2000). Bacterial lipopolysaccharide acts as an adjuvant to induce autoimmune arthritis in mice. Immunology 4, 607-614.
107. Zwenger, S., and Basu, C. (2008). Plant terpenoids: applications and future potentials. Biotechnol. Mol. Biol. Rev. 3, 1-7.